Revive Therapeutics Ltd. (FRA:31R)

Market Cap	8.08M +51.9%
Revenue (ttm)	n/a
Net Income	-6.60M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0110
Previous Close	0.0105
Day's Range	0.0110 - 0.0110
52-Week Range	0.0005 - 0.0555
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 16, 2026

About Revive Therapeutics

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphe...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Michael Frank
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 31R

Financial Performance

Financial numbers in CAD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error